Increased protein and lipid oxidative damage in mitochondria isolated from lymphocytes from patients with alzheimer's disease: Insights into the role of oxidative stress in alzheimer's disease and initial investigations into a potential biomarker for this dementing disorder

Journal of Alzheimer's Disease

Volumn 24, Issue 1, 2011, Pages 77-84

  Sultana, Rukhsana ^a   Mecocci, Patrizia ^b   Mangialasche, Francesca ^b   Cecchetti, Roberta ^b   Baglioni, Mauro ^b   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

3 nitrotyrosine; Alzheimer's disease; lymphocytes; mitochondria; oxidative stress; protein carbonyls; protein bound 4 hydroxy 2 trans nonenal

Indexed keywords

3 NITROTYROSINE; BIOLOGICAL MARKER; CARBONYL DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; ENERGY METABOLISM; FEMALE; HUMAN; HUMAN CELL; LIPID OXIDATION; LIPID PEROXIDATION; LYMPHOCYTE; MALE; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 79955658979     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-101425     Document Type: Article

References (53)

1. Kurz T, Terman A, Brunk UT (2007) Autophagy, ageing and apoptosis: the role of oxidative stress and lysosomal iron. Arch Biochem Biophys 462, 220-230. (Pubitemid 46856317)
2. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766. (Pubitemid 32267077)
3. Boyd-Kimball D, Mohmmad Abdul H, Reed T, Sultana R, Butterfield DA (2004) Role of phenylalanine 20 in Alzheimer's amyloid beta-peptide (1-42)-induced oxida-tive stress and neurotoxicity. Chem Res Toxicol 17, 1743-1749. (Pubitemid 39665568)
4. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA (2005) Proteomic iden-tification of proteins specifically oxidized by intracerebral injection of amyloid beta-peptide (1-42) into rat brain: impli-cations for Alzheimer's disease. Neuroscience 132, 313-324. (Pubitemid 40417906)
5. Butterfield DA, Boyd-Kimball D (2005) The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703, 149-156. (Pubitemid 40170438)
6. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang J, Sultana R, Bredesen DE (2010) In vivo oxidative stress in brain of Alzheimer disease transgenic mice: requirement for methio-nine 35 in amyloid beta-peptide of APP Free Radic Biol Med 48, 136-144.
7. Markesbery WR (1997) Oxidative stress hypothesis in Alzhei-mer's disease. Free Radic Biol Med 23, 134-147. (Pubitemid 27217017)
8. Fukuda M, Kanou F, Shimada N, Sawabe M, Saito Y, Murayama S, Hashimoto M, Maruyama N, Ishigami A (2009) Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer's dis-ease. Biomed Res 30, 227-233.
9. Markesbery WR, Lovell MA (1998) 4-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19, 33-36. (Pubitemid 28167792)
10. Mecocci P, Polidori MC, Cherubini A, Ingegni T, Mattioli P, Catani M, Rinaldi P, Cecchetti R, Stahl W, Senin U, Beal MF (2002) Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease. Arch Neurol 59, 794-798. (Pubitemid 34517762)
11. Montine KS, Olson SJ, Amarnath V, Whetsell WO Jr, Graham DG, Montine TJ (1997) Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is asso-ciated with inheritance of APOE4. Am J Pathol 150, 437-443. (Pubitemid 27073773)
12. Pratico D, Sung S (2004) Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. JAlzheimers Dis 6, 171-175. (Pubitemid 38560253)
13. Volkel W, Sicilia T, Pahler A, Gsell W, Tatschner T, Jellinger K, Leblhuber F, Riederer P, Lutz WK, Gotz ME (2006) Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochem Int 48, 679-686.
14. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RA (1998) Electrochemical analysis ofprotein nitroty-rosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci 18, 8126-8132. (Pubitemid 28464991)
15. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA (2001) The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. JNeurochem 78, 413-416. (Pubitemid 32664423)
16. Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G (2008) Nucleic acid oxidation inAlzheimerdisease. Free Radic Biol Med 44, 1493-1505.
17. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M, Hayashi T, Yamaguchi H, Shimohama S, Lee HG, Zhu X, Smith MA, Perry G (2010) Intraneuronal amyloid beta accu-mulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 37, 731-737.
18. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochon-drial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. Faseb J19, 2040-2041. (Pubitemid 41759758)
19. Reddy PH (2009) Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 218, 286-292.
20. Sultana R, Butterfield DA (2009) Oxidatively modi-fied, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. JBioenerg Biomembr 41, 441-446.
21. Ankarcrona M, Mangialasche F, Winblad B (2010) Rethink-ing Alzheimer's disease therapy: are mitochondria the key? J Alzheimers Dis 20(Suppl 2), S579-S590.
22. Gustaw-Rothenberg K, Lerner A, Bonda DJ, Lee HG, Zhu X, Perry G, Smith MA (2010) Biomarkers in Alzheimer's disease: past, present and future. Biomark Med 4, 15-26.
23. Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L (2005) Searching for the role and the most suit-able biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 26, 587-595. (Pubitemid 40228750)
24. Gibson GE, Zhang H (2001) Abnormalities in oxidative pro-cesses in non-neuronal tissues from patients with Alzheimer's disease. J Alzheimers Dis 3, 329-338. (Pubitemid 32577637)
25. Folstein MF, Folstein SE, McHugh PR (1975) 'Mini-mental state'. A practical method for grading the cognitive state of patients forthe clinician. J Psychiatr Res 12, 189-198.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's dis-ease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Ser-vices Task Force on Alzheimer's Disease. Neurology 34, 939-944. (Pubitemid 14076461)
27. Sultana R, Ravagna A, Mohmmad-Abdul H, Calabrese V, Butterfield DA (2005) Ferulic acid ethyl ester protects neu-rons against amyloid beta-peptide(1-42)- induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 92, 749-758. (Pubitemid 40229546)
28. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and bio-chemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81-128. (Pubitemid 121003917)
29. Berlett BS, Stadtman ER (1997) Protein oxidation in aging, disease, andoxidativestress. J Biol Chem 272, 20313-20316. (Pubitemid 27355575)
30. Butterfield DA, Castegna A, Lauderback CM, Drake J (2002) Evidence that amyloid beta-peptide-induced lipid peroxida-tion and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23, 655-664. (Pubitemid 35217687)
31. Butterfield DA, Stadtman ER (1997) Protein oxidation pro-cesses in aging brain. Adv Cell Aging Gerontol 2, 161-191.
32. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, But-terfield DA (2006) Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8, 1975-1986. (Pubitemid 46489625)
33. Mecocci P, Polidori MC, Ingegni T, Cherubini A, Chionne F, Cecchetti R, Senin U (1998) Oxidative damage to DNA in lymphocytes from AD patients. Neurology 51, 1014-1017. (Pubitemid 28473393)
34. Xu W, Kawarabayashi T, Matsubara E, Deguchi K, Murakami T, Harigaya Y, Ikeda M, Amari M, Kuwano R, Abe K, Shoji M (2008) Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Res 1219, 169-179.
35. Fukumoto H, Tennis M, Locascio JJ, Hyman BT, Growdon JH, Irizarry MC (2003) Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol 60, 958-964. (Pubitemid 36858355)
36. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E (2000) Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amy-loid 7, 245-258.
37. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M (1999) Lipoprotein-free amyloidogenic peptides in plasma are ele-vated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45, 537-541. (Pubitemid 29165825)
38. Glabe CC (2005) Amyloid accumulation and pathogensis of Alzheimer's disease: significance of monomeric, oligomeric and fibrillar Abeta. Subcell Biochem 38, 167-177.
39. Molina JA, de Bustos F, Jimenez-Jimenez FJ, Benito-Leon J, Gasalla T, Orti-Pareja M, Vela L, Bermejo F, Martin MA, Campos Y, Arenas J (1997) Respiratory chain enzyme activ-ities in isolated mitochondria of lymphocytes from patients with Alzheimer's disease. Neurology 48, 636-638. (Pubitemid 27120098)
40. Moreira PI, Harris PL, Zhu X, Santos MS, Oliveira CR, Smith MA, Perry G (2007) Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J Alzheimers Dis 12, 195-206. (Pubitemid 47509369)
41. Crouch PJ, Cimdins K, Duce JA, Bush AI, Trounce IA (2007) Mitochondriain aging and Alzheimer's disease. Rejuvenation Res 10, 349-357.
42. Dimou E, Booij J, Rodrigues M, Prosch H, Attems J, Knoll P, Zajicek B, Dudczak R, Mostbeck G, Kuntner C, Langer O, Bruecke T, Mirzaei S (2009) Amyloid PET and MRI in Alzheimer's disease and mild cognitive impairment. Curr Alzheimer Res 6, 312-319.
43. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33, 562-571. (Pubitemid 34874977)
44. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA (2002) Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase- related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82, 1524-1532.
45. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markes-bery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85, 1394-1401. (Pubitemid 36702552)
46. Reed T, Perluigi M, Sultana R, Pierce WM, Klein JB, Turner DM, Coccia R, Markesbery WR, Butterfield DA (2008) Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neuro-biolDis30, 107-120.
47. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA (2006) Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alter-ations in AD. Neurobiol Aging 27, 1564-1576. (Pubitemid 44344840)
48. Sultana R, Poon HF, Cai J, Pierce WM, Merchant M, Klein JB, Markesbery WR, Butterfield DA (2006) Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis 22, 76-87.
49. Perluigi M, Sultana R, Cenini G, Di Domenico F, Memo M, Pierce WM, Coccia R, Butterfield DA (2009) Redox pro-teomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis. Proteomics Clin Appl 3, 682-693.
50. Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE (2005) Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 57, 695-703. (Pubitemid 40628858)
51. Sims NR (1990) Altered glucose metabolism in Alzheimer's disease. Ann Neurol 27, 691-693.
52. Casley CS, Canevari L, Land JM, Clark JB, Sharpe MA (2002) Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80, 91-100. (Pubitemid 34614581)
53. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ, 2nd, Kaye JA, Morrow JD (2002) Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52, 175-179. (Pubitemid 34810597)